Chiral Quest (Suzhou) Co., Ltd. operates world-class asymmetric hydrogenation technology. Application of our unique catalysts provides advantages in R&D and manufacturing. We are committed to the development and production of safe, economic and high-quality intermediates for the pharmaceutical industry. We provide global pharmaceutical companies with customized research and production services for intermediates, RSMs and GMP intermediates.

Chiral Quest (Suzhou) Co., Ltd. merged with Jiangxi LongLife Bio-pharmaceutical Co., Ltd. in 2012 and with Suzhou Pengxu PharmaTech Co., Ltd. in 2020. In 2019, Suzhou LongLife Bio-Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Suzhou Pengxu, was established. Chiral Quest is the parent company of the group, Jiangxi LongLife is the manufacturing site, and Suzhou LongLife is the research and development center. In addition, the company has offices in the United States and the United Kingdom.

Chiral Quest (Suzhou) Co., Ltd. has more than 600 employees, including nearly 150 people in the R&D center, all of them have obtained bachelor's degree or above. The core R&D personnel all have masters or Ph.D. degree. 

We uphold the concepts of "Integrity, responsibility, execution, teamwork, innovation, and communication", and strive to provide global customers with leading technology, high-quality services and products.​

Integrity, responsibility, execution, teamwork, innovation, and communication